Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis

References

• Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016;113(27-28):470–476. doi:10.3238/arztebl.2016.0470.
   PubMed Web of Science ®Google Scholar
• Shank BR, Brown VT, Schwartz RN. Multiple myeloma maintenance therapy: a review of the pharmacologic treatment. J Oncol Pharm Pract. 2015;21(1):36–51. doi:10.1177/1078155213514468.
   PubMed Web of Science ®Google Scholar
• Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11(11):1427–1436. doi:10.1023/a:1026548226770.
   PubMed Web of Science ®Google Scholar
• Kagoya Y, Nannya Y, Kurokawa M. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res. 2012;36(8):1016–1021. doi:10.1016/j.leukres.2012.04.001.
   PubMed Web of Science ®Google Scholar
• Alonso R, Cedena MT, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020;4(10):2163–2171. doi:10.1182/bloodadvances.2020001508.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791. doi:10.1056/NEJMoa1114138.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Špička I, Quach H, et al. Ixazomib as postinduction maintenance for patients With newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38(34):4030–4041. doi:10.1200/jco.20.02060.
   PubMed Web of Science ®Google Scholar
• Zweegman S, Stege CAM, Haukas E, et al. Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. 2020;105(12):2879–2882. doi:10.3324/haematol.2019.240374.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030–6038. doi:10.1158/1078-0432.Ccr-12-3211.
   PubMed Web of Science ®Google Scholar
• Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica. 2021;106(7):1957–1967. doi:10.3324/haematol.2020.247130.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Teruel AI, et al. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017;31(9):1922–1927. doi:10.1038/leu.2017.35.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2019;393(10168):253–264. doi:10.1016/s0140-6736(18)33003-4.
   PubMed Web of Science ®Google Scholar
• Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629. doi:10.1016/s1470-2045(15)00389-7.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431–e442. doi:10.1016/S2352-3026(17)30140-0.
   PubMed Web of Science ®Google Scholar
• Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705–1720. doi:10.1016/s1470-2045(21)00535-0.
   PubMed Web of Science ®Google Scholar
• Bringhen S, D’Agostino M, Paris L, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica. 2020;105(7):1937–1947. doi:10.3324/haematol.2019.226407.
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1378–1390. doi:10.1016/s1470-2045(21)00428-9.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, van der Holt B, Minnema MC, et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018;5(10):e479–e492. doi:10.1016/s2352-3026(18)30149-2.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Tóthová E, et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica. 2010;95(9):1548–1554. doi:10.3324/haematol.2009.020586.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Martínez-López J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120(13):2581–2588. doi:10.1182/blood-2012-05-427815.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905. doi:10.1056/NEJMoa1402888.
   PubMed Web of Science ®Google Scholar
• Brioli A, Manz K, Pfirrmann M, et al. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). J Cancer Res Clin Oncol. 2020;146(3):749–759. doi:10.1007/s00432-019-03101-z.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet (London England). 2020;395(10218):132–141. doi:10.1016/s0140-6736(19)32956-3.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–1769. doi:10.1056/NEJMoa1112704.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma. Cancer. 2019;125(14):2364–2382. doi:10.1002/cncr.32065.
   PubMed Web of Science ®Google Scholar
• Balitsky AK, Karkar A, McCurdy A, et al. Maintenance therapy in transplant ineligible adults with newly-diagnosed multiple myeloma: A systematic review and meta-analysis. Eur J Haematol. 2020;105(5):626–634. doi:10.1111/ejh.13496.
   PubMed Web of Science ®Google Scholar
• Chen R, Chen B, Zhang X, et al. Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials. Discov Med. 2016;22(121):189–199.
   PubMed Web of Science ®Google Scholar
• Gay F, Jackson G, Rosiñol L, et al. Maintenance treatment and survival in patients With myeloma: A systematic review and network meta-analysis. JAMA Oncol. 2018;4(10):1389–1397. doi:10.1001/jamaoncol.2018.2961.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. J Clin Oncol. 2017;35(29):3279–3289. doi:10.1200/jco.2017.72.6679.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29. doi:10.1182/blood-2017-06-740944.
   PubMed Web of Science ®Google Scholar
• Paul B, Hamadeh I, Atrash S, et al. Daratumumab subcutaneous formulation for the treatment of multiple myeloma. Expert Opin Biol Ther. 2020;20(11):1253–1259. doi:10.1080/14712598.2020.1806231.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Szymaniak-Vits M, Ajayi S, et al. Carfilzomib. Recent Results Cancer Res. 2018;212:265–283. doi:10.1007/978-3-319-91439-8_13.
   PubMedGoogle Scholar